Tech Company Financing Transactions
Bioxodes Funding Round
Bioxodes secured a $2.8 million Series A funding round on 2/12/2025. Backers included private investors.
Transaction Overview
Company Name
Announced On
2/12/2025
Transaction Type
Venture Equity
Amount
$2,800,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to deliver full results from BIRCH, its Phase 2a trial of BIOX-101 to treat intracerebral hemorrhage (ICH), an orphan disease with no currently approved therapeutic intervention, and prepare for the launch of a potentially registrational Phase 2b trial of BIOX-101 for ICH.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Parc d'activités Aéropole Rue Santos-Dumont, 1
Gosselies, 6041
BE
Gosselies, 6041
BE
Phone
Undisclosed
Website
Email Address
Overview
Founded by an experienced group of seasoned healthcare and biotech executives with extensive experience in research, drug development, and commercialisation, Bioxodes is developing a portfolio of high value products derived from natural sources based on research conducted by Prof. Edmond Godfroid. The research was conducted in collaboration withacademic groups from Université Catholique de Louvain, Facultés Universitaires Notre Dame de la Paix Namur, and Université de Liège as well as with the Université de Neuchâtel, Switzerland.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Marc Dechamps
Chief Operating Officer
Edmond Godfroid
Browse more venture capital transactions:
Prev: 2/12/2025: Suger venture capital transaction
Next: 2/12/2025: HowNow venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records on this site are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs